Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space
Start-Up Was First To Start A Phase III Trial
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.
